http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2635523-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cdb3a5e4e6d418090dbafa8386f4e490 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-133 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-133 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-04 |
| filingDate | 2016-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_299586495f95349a06012e74c96ed9b5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbd6026981fc0bdb01ee0c6a7e54e09c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85170832606bca22cabb006e91bc53ce |
| publicationDate | 2017-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2635523-C2 |
| titleOfInvention | Method for cardioplegia |
| abstract | FIELD: medicine. n SUBSTANCE: to stop the heart and maintain it in a stopped state, a cardioplegic solution is used which is obtained from the following components: potassium chloride - 7.45 g; magnesium sulfate - 2.34 g; trometamol - 0.5 g; mannitol - 35.9 g; distilled water - up to 1000 ml, with introduction of 1 M hydrochloric acid until a pH of 7.6-8.0, which is mixed with blood from the oxygenator in a ratio of 1:1 to 1:4 and injected into the heart at a rate of 100-300 ml/min using at least 400 ml of solution; and to maintain the asystole, a cardioplegic solution is used which is obtained from the following components: potassium chloride - 2.125 g; magnesium sulfate - 2.34 g; trometamol - 0.5 g; mannitol - 58.28 g; distilled water - up to 1000 ml, with introduction of 1 M hydrochloric acid until a pH of 7.6-8.0, which is mixed with blood from the oxygenator in a ratio of 1:4 and injected into the heart at a rate of 100-150 ml/min. n EFFECT: improved safety of cardioplegia using different cardioplegic solutions. n 3 ex |
| priorityDate | 2016-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.